# A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

> **NCT04951076** · PHASE2 · COMPLETED · sponsor: **Bionomics Limited** · enrollment: 212 (actual)

## Conditions studied

- Post-Traumatic Stress Disorder

## Interventions

- **DRUG:** BNC210
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04951076
- **Lead sponsor:** Bionomics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-27
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-08-14
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951076, "A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04951076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*